Senseonics(US:SENS) Globenewswire·2026-02-19 13:00Core Insights - Sequel Med Tech and Senseonics have announced the full availability of the twiist™ Automated Insulin Delivery (AID) System integrated with the Eversense® 365 Continuous Glucose Monitoring (CGM) system across the U.S., marking a significant advancement in diabetes management [1][4]. Company Overview - Sequel Med Tech, headquartered in Manchester, N.H., focuses on developing transformative drug delivery technologies, including the twiist AID system, which aims to simplify disease management [9]. - Senseonics Holdings, Inc. specializes in long-term implantable glucose monitoring products, with the Eversense 365 being the only one-year CGM available, providing continuous glucose monitoring for up to 365 days [10][12]. Product Features - The twiist AID system is the first to be compatible with the Eversense 365 CGM, significantly reducing the need for frequent sensor changes and re-pairing while maintaining high accuracy [2][5]. - The twiist system utilizes the twiist Loop™ algorithm to automatically adjust insulin delivery based on real-time CGM data, offering features like activity presets and a wide glucose target range [7]. Market Impact - The integration of twiist with Eversense 365 is expected to enhance diabetes management by providing users with more tools for glucose control, increased convenience, and greater flexibility [3][4]. - The national availability of this combination is seen as a pivotal moment in reducing the daily burden faced by individuals with diabetes, allowing them to focus more on their lives rather than device management [4][5].